- IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, SeaportWith major backing from new investors, Celea Therapeutics hopes to follow in the footsteps of its siblings Seaport Therapeutics and Karuna Therapeutics. Celea has corralled $180 million to see ifEndpoints · 26d ago↗ source
- Roche KRAS drug succeeds in head-to-head lung cancer studyThe Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.BioPharma Dive · 26d ago↗ source
- STAT+: Roche drug sets new standard for KRAS-driven lung cancerBiotech's bull market, Vertex's gene therapy expansion, and more news from The ReadoutSTAT · 26d ago↗ source